The Kent biotechnology spinout raised the capital from backers including XGEN Venture and the British Business Bank to push its lead treatment into clinical evaluation.
"Refractory epilepsy is a devastating condition causing unpredictable and life-threatening seizures, and affecting millions of patients worldwide. Our novel gene therapy EPY201 delivered directly to the seizure focus has the potential to stop seizures with a single, minimally invasive administration. In doing so, it will change the way refractory epilepsy has been treated for decades. We are proud to have the support of such high calibre investors as we progress into clinical trials."
Beringea backs premium bike resale platform Cycle Exchange with a £2.4m injection.
"Cycle Exchange has quickly risen to be the UK’s leading resale platform for high-end bikes, driven by an uncompromising approach to ensuring bikes are refurbished to like new condition. This is reflected in their exceptional customer reviews and their partnerships with iconic brands such as Pinarello, Brompton, and British Cycling."
Sofina led the round with participation from Balderton Capital to support product development and market expansion.
"This round is a strong endorsement of our progress and our mission to modernise transport management. Since our Series A we’ve grown revenue, customers and team at an exceptional pace, while remaining highly capital efficient. The Series B funding allows us to continue investing and grow the team so that we can keep offering the same level of customer service."
The round was led by Soulmates Ventures with backing from institutional investors and the S100 Angel Investment Club.
"The home is the quiet giant of electrification. Over 70% of charging already happens there. Accurate, automated payments give businesses confidence to electrify faster, while cutting costs and carbon. Thanks to our investors and partners, we’re now bringing that capability to fleets across Europe."
